Heart Failure and Cardiac Transplant Unit, Department of Cardiology, Hospital Universitari de Bellvitge, Institut d'Investigació Biomédica de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Eur J Heart Fail. 2010 Nov;12(11):1159-62. doi: 10.1093/eurjhf/hfq165. Epub 2010 Sep 20.
Treatment of anaemia in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction has traditionally focused on erythropoietin-stimulating agents. However, recent studies have shown that treatment with intravenous (IV) iron can improve the symptoms and quality of life in patients with CHF and iron deficiency (ID), with or without anaemia. The management of ID is becoming an important therapeutic target in patients with CHF, and in this article, we will review iron metabolism in the context of anaemia and heart failure. We will also focus on the importance of diagnosing and treating ID, preferably with IV iron preparations, in patients with CHF.
慢性心力衰竭（CHF）和左心室射血分数降低的患者的贫血治疗传统上侧重于促红细胞生成素刺激剂。然而，最近的研究表明，静脉（IV）铁治疗可以改善 CHF 和缺铁（ID）患者的症状和生活质量，无论是否存在贫血。ID 的管理正在成为 CHF 患者的一个重要治疗目标，在本文中，我们将在贫血和心力衰竭的背景下综述铁代谢。我们还将重点讨论诊断和治疗 ID 的重要性，最好使用 IV 铁制剂，用于 CHF 患者。
